Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review.
Adrenocortical adenoma
Hyperaldosteronism
Hypertension
Paraganglioma
Pheochromocytoma
Journal
Journal of Yeungnam medical science
ISSN: 2799-8010
Titre abrégé: J Yeungnam Med Sci
Pays: Korea (South)
ID NLM: 9918333886606676
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
19
07
2024
accepted:
03
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Most cases of high blood pressure have no identifiable cause, termed essential hypertension; however, in approximately 15% of cases, hypertension occurs due to secondary causes. Primary aldosteronism (PA) and pheochromocytoma and paraganglioma (PPGL) are representative endocrine hypertensive diseases. The differentiation of endocrine hypertension provides an opportunity to cure and prevent target organ damage. PA is the most common cause of secondary hypertension, which significantly increases the risk of cardiovascular disease compared to essential hypertension; thus, patients with clinical manifestations suggestive of secondary hypertension should be screened for PA. PPGL are rare but can be fatal when misdiagnosed. PPGL are the most common hereditary endocrine tumors; therefore, genetic testing using next-generation sequencing panels is recommended. Herein, we aimed to summarize the characteristic clinical symptoms of PA and PPGL and when and how diagnostic tests and treatment strategies should be performed.
Identifiants
pubmed: 39295528
pii: jyms.2024.00752
doi: 10.12701/jyms.2024.00752
doi:
Types de publication
Journal Article
Langues
eng